Danish insulin giant Novo Nordisk (NOV: N) reported sales of 61.9 billion ($11.3 billion) Danish kroner in the first nine months of 2013, up 13% the like 2012 period. Its shares were down 4.3% in morning trading after the results missed analysts’ forecasts.
The company’s financial results released today (October 31) show that it made gross profit of 51.1 billion kroner, a 9% increase from 46.7 billion kroner in the same period last year. Operating profit was 24.1 billion kroner, up 10%, in the first nine months and 7.99 billion kroner in the third quarter, under analysts’ estimates of 8.19 billion kroner according to Reuters.
Net profit increased by 22% to 19.1 billion kroner. Diluted earnings per share were 35.39 kroner up 25% from 28.32 kroner last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze